Neurosense Therapeutics Ltd (NRSN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Neurosense Therapeutics Ltd (NRSN) has a cash flow conversion efficiency ratio of 1.177x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.84 Million) by net assets ($-1.56 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Neurosense Therapeutics Ltd (NRSN) total market value for the company's overall valuation and market capitalisation.
Neurosense Therapeutics Ltd - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how Neurosense Therapeutics Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Neurosense Therapeutics Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Neurosense Therapeutics Ltd ranked by their cash flow conversion efficiency. See Neurosense Therapeutics Ltd cash debt coverage ratio to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Taiwan Thick-Film Ind
TWO:6246
|
0.120x |
|
Playtech Plc
LSE:PTEC
|
-0.001x |
|
Connection Technology Systems
TWO:3672
|
-0.009x |
|
Pharma Equity Group A/S Cl A
CO:PEG
|
-0.261x |
|
OXE Marine AB
ST:OXE
|
-0.326x |
|
Raptis Group Ltd
AU:RPG
|
0.037x |
|
Genomtec S.A.
WAR:GMT
|
-0.262x |
|
FACILITIES BY ADF LS-01
F:ZC8
|
N/A |
Annual Cash Flow Conversion Efficiency for Neurosense Therapeutics Ltd (2019–2025)
The table below shows the annual cash flow conversion efficiency of Neurosense Therapeutics Ltd from 2019 to 2025. View today's stock price for Neurosense Therapeutics Ltd for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-1.56 Million | $-7.67 Million | 4.917x | +225.32% |
| 2024-12-31 | $2.58 Million | $-10.13 Million | -3.924x | -182.62% |
| 2023-12-31 | $-1.76 Million | $-8.35 Million | 4.749x | +451.78% |
| 2022-12-31 | $5.62 Million | $-7.59 Million | -1.350x | -690.04% |
| 2021-12-31 | $9.01 Million | $-1.54 Million | -0.171x | +83.80% |
| 2020-12-31 | $659.00K | $-695.00K | -1.055x | -66.35% |
| 2019-12-31 | $918.00K | $-582.00K | -0.634x | -- |
About Neurosense Therapeutics Ltd
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for t… Read more